Health Care Down After Pfizer, Novo Nordisk Earnings -- Health Care Roundup

Dow Jones

02/04

Health-care companies fell after weak earnings.

Pfizer declined as weakened COVID-19 drug demand weighed on quarterly sales.

Shares of Danish obesity-drug maker Novo Nordisk plunged after it warned that it expects lower prices for Ozempic and Wegovy in the U.S. to weigh on 2026 sales, dragging them 5%-to-13% lower than 2025 levels around 309.06 billion Danish kroner, or about $48.79 billion.

Merck shares rose after the Big Pharma company cited strong demand for oncology, respiratory, and cardiometabolic drugs for its brisk quarterly sales growth.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

February 03, 2026 17:32 ET (22:32 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2608386159"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2608386159\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2608386159?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-04 06:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608386159","market":"other","top_or_hot":-1,"title":"Health Care Down After Pfizer, Novo Nordisk Earnings -- Health Care Roundup","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Health-care companies fell after weak earnings. \n</p>\n<p>\n  Pfizer declined as weakened COVID-19 drug demand weighed on quarterly sales. \n</p>\n<p>\n  Shares of Danish obesity-drug maker <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> plunged after it warned that it expects  lower prices for Ozempic and Wegovy in the U.S. to weigh on 2026 sales, dragging them 5%-to-13% lower than 2025 levels around 309.06 billion Danish kroner, or about $48.79 billion. \n</p>\n<p>\n  Merck shares rose after the Big Pharma company cited strong demand for oncology, respiratory, and cardiometabolic drugs for its brisk quarterly sales growth. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 03, 2026 17:32 ET (22:32 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Health Care Down After Pfizer, Novo Nordisk Earnings -- Health Care Roundup</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHealth Care Down After Pfizer, Novo Nordisk Earnings -- Health Care Roundup\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-04 06:32</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Health-care companies fell after weak earnings. \n</p>\n<p>\n  Pfizer declined as weakened COVID-19 drug demand weighed on quarterly sales. \n</p>\n<p>\n  Shares of Danish obesity-drug maker <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> plunged after it warned that it expects  lower prices for Ozempic and Wegovy in the U.S. to weigh on 2026 sales, dragging them 5%-to-13% lower than 2025 levels around 309.06 billion Danish kroner, or about $48.79 billion. \n</p>\n<p>\n  Merck shares rose after the Big Pharma company cited strong demand for oncology, respiratory, and cardiometabolic drugs for its brisk quarterly sales growth. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 03, 2026 17:32 ET (22:32 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999002232.USD","symbol_name":"Allianz Global High Payout USD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2608386159","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608386159","pubTimestamp":1770157920,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Pfizer declined as weakened COVID-19 drug demand weighed on quarterly sales.Shares of Danish obesity-drug maker Novo Nordisk plunged after it warned that it expects  lower prices for Ozempic and Wegovy in the U.S. to weigh on 2026 sales, dragging them 5%-to-13% lower than 2025 levels around 309.06 billion Danish kroner, or about $48.79 billion.Merck shares rose after the Big Pharma company cited strong demand for oncology, respiratory, and cardiometabolic drugs for its brisk quarterly sales growth.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"SG9999002232.USD":"Allianz Global High Payout USD","LABU":"三倍做多标普生物-Direxion","PFE":"辉瑞","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","MRK":"默沙东","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4592":"伊斯兰概念","XBI":"SPDR S&P Biotech ETF","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU0122379950.USD":"贝莱德世界健康科学A2","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","BK4588":"碎股","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU0058720904.USD":"联博国际健康护理基金A","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4007":"制药","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","SG9999001176.USD":"United Global Healthcare Acc USD","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","NVO":"诺和诺德","BK4581":"高盛持仓","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BK4532":"文艺复兴科技持仓","BK4599":"减肥药","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus"},"translate_title":"辉瑞和诺和诺德盈利后医疗保健下降——医疗保健综述","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XBI":0.6,"LABU":0.6,"PFE":1.92,"MRK":1.87,"NVO":1.94},"content_text":"Health-care companies fell after weak earnings. \n\n\n  Pfizer declined as weakened COVID-19 drug demand weighed on quarterly sales. \n\n\n  Shares of Danish obesity-drug maker Novo Nordisk plunged after it warned that it expects  lower prices for Ozempic and Wegovy in the U.S. to weigh on 2026 sales, dragging them 5%-to-13% lower than 2025 levels around 309.06 billion Danish kroner, or about $48.79 billion. \n\n\n  Merck shares rose after the Big Pharma company cited strong demand for oncology, respiratory, and cardiometabolic drugs for its brisk quarterly sales growth. \n\n\n \n\n\n  Write to Rob Curran at rob.curran@dowjones.com \n\n\n  (END) Dow Jones Newswires\n\n\n  February 03, 2026 17:32 ET (22:32 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}